TrialInvestigational new drugs2011

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.

Manish A Shah et al.PubMed ↗Publisher ↗

No numbers read from the abstract.